the development of autoimmune diseases in some patients treated with d-penicillamine ( dpa ) suggests that the reported occurrence of a conduction disorder at the neuromuscular junction and the development of a reversible myasthenia gravis in rheumatoid disease , progressive systemic sclerosis or wilson 's disease after the use of dpa are part of a general predisposition for autoimmune disease related to dpa therapy .
C0019202
wilson 's disease
C0030817
dpa